Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

Abstract

Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.